Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

The changes come after a rough quarter for Target, with sales at stores open for at least a year tumbling 3.8% compared to ...

Under Target's current policy, the company will match the price of store-bought products if customers "then find the ...

Morse Asset Management Inc has significantly increased its stake in Regeneron Pharmaceuticals, boosting its share count by a ...

Target's decision to cease price matching with competitors like Amazon and Walmart marks a significant shift. Currently, ...

Reuters is tracking how companies are responding to the threat posed by <a href=" target="_blank" rel="noopener noreferrer ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...

Target to stop price matching retailers The company will no longer match pricing for identical items at places such as Walmart and Amazon.

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...